Pear Therapeutics Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pear Therapeutics (PEAR) Tops Q1 EPS by 7c
May 16, 2022 4:28 PM EDTPear Therapeutics (NASDAQ: PEAR) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.4 million.
GUIDANCE:
Pear Therapeutics sees FY2022 revenue of $22 million.
For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.
... More